Decreased Mortality in Coronavirus Disease 2019 Patients Treated With Tocilizumab: A Rapid Systematic Review and Meta-analysis of Observational Studies
Jishnu Malgie 1, Jan W Schoones 2, Bart G Pijls 1Affiliations expand
- PMID: 32964913
- PMCID: PMC7543350
- DOI: 10.1093/cid/ciaa1445
Free PMC article
Background: We systematically reviewed the literature to answer the following research questions: (1) Does interleukin 6 (IL-6) (receptor) antagonist therapy reduce mortality in coronavirus disease 2019 (COVID-19) patients compared to patients not treated with IL-6 (receptor) antagonists; and (2) is there an increased risk of side effects in COVID-19 patients treated with IL-6 (receptor) antagonists compared to patients not treated with IL-6 (receptor) antagonists?
Methods: We systematically searched PubMed, PMC PubMed Central, Medline, World Health Organization COVID-19 Database, Embase, Web of Science, Cochrane Library, Emcare, and Academic Search Premier (through 30 June 2020). Random effects meta-analysis was used to pool the risk ratios and risk differences of individual studies. Risk of bias was appraised using the Methodological Index for Non-randomized Studies (MINORS) checklist.
Results: The search strategy retrieved 743 unique titles, of which 10 studies (all on tocilizumab [TCZ]) comprising 1358 patients were included. Nine of 10 studies were considered to be of high quality. Meta-analysis showed that the TCZ group had lower mortality than the control group. The risk ratio was 0.27 (95% confidence interval [CI], .12-.59) and the risk difference was 12% (95% CI, 4.6%-20%) in favor of the TCZ group. With only a few studies available, there were no differences observed regarding side effects.
Conclusions: Our results showed that mortality was 12% lower for COVID-19 patients treated with TCZ compared with those not treated with TCZ. The number needed to treat was 11, suggesting that for every 11 (severe) COVID-19 patients treated with TCZ, 1 death is prevented. These results require confirmation by randomized controlled trials.
Keywords: COVID-19; IL-6 receptor antagonists; mortality; tocilizumab.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
- Reply to Huang et al.Malgie J, Schoones JW, Pijls BG.Clin Infect Dis. 2021 Jun 15;72(12):e1157-e1158. doi: 10.1093/cid/ciaa1739.PMID: 33201173 No abstract available.
- Impact of Tocilizumab on the Mortality of Patients With Coronavirus Disease 2019.Huang YT, Chao CM, Lai CC.Clin Infect Dis. 2021 Jun 15;72(12):e1156-e1157. doi: 10.1093/cid/ciaa1738.PMID: 33201178 Free PMC article. No abstract available.
- The Misleading “Pooled Effect Estimate” of Crude Data from Observational Studies at Critical Risk of Bias: The Case of Tocilizumab in Coronavirus Disease 2019 (COVID-19).Tleyjeh IM.Clin Infect Dis. 2021 Jun 15;72(12):e1154-e1155. doi: 10.1093/cid/ciaa1735.PMID: 33201228 Free PMC article. No abstract available.
- Compiling Observational Research During a Pandemic: A Necessary Bridge.Moehring RW, Holland TL.Clin Infect Dis. 2021 Jun 1;72(11):e750-e752. doi: 10.1093/cid/ciaa1705.PMID: 33306094 Free PMC article. No abstract available.
- Reply to Tleyjeh.Malgie J, Schoones JW, Pijls BG.Clin Infect Dis. 2021 Jun 15;72(12):e1155-e1156. doi: 10.1093/cid/ciaa1736.PMID: 33340049 No abstract available.
- Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, Altannir Y, Al-Tannir M, Tleyjeh R, Hassett L, Kashour T.Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.PMID: 33161150 Free PMC article.
- Interleukin-6 blocking agents for treating COVID-19: a living systematic review.Ghosn L, Chaimani A, Evrenoglou T, Davidson M, Graña C, Schmucker C, Bollig C, Henschke N, Sguassero Y, Nejstgaard CH, Menon S, Nguyen TV, Ferrand G, Kapp P, Riveros C, Ávila C, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P, Boutron I.Cochrane Database Syst Rev. 2021 Mar 18;3:CD013881. doi: 10.1002/14651858.CD013881.PMID: 33734435
- IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, Marcos-Jiménez A, Sánchez-Alonso S, Fernández-Díaz C, Alcaraz-Serna A, Mateu-Albero T, Rodríguez-Cortes P, Sánchez-Cerrillo I, Esparcia L, Martínez-Fleta P, López-Sanz C, Gabrie L, Del Campo Guerola L, Suárez-Fernández C, Ancochea J, Canabal A, Albert P, Rodríguez-Serrano DA, Aguilar JM, Del Arco C, de Los Santos I, García-Fraile L, de la Cámara R, Serra JM, Ramírez E, Alonso T, Landete P, Soriano JB, Martín-Gayo E, Fraile Torres A, Zurita Cruz ND, García-Vicuña R, Cardeñoso L, Sánchez-Madrid F, Alfranca A, Muñoz-Calleja C, González-Álvaro I; REINMUN-COVID Group.J Allergy Clin Immunol. 2021 Jan;147(1):72-80.e8. doi: 10.1016/j.jaci.2020.09.018. Epub 2020 Sep 30.PMID: 33010257 Free PMC article. Clinical Trial.
- Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.Berardicurti O, Ruscitti P, Ursini F, D’Andrea S, Ciaffi J, Meliconi R, Iagnocco A, Cipriani P, Giacomelli R.Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1247-1254. Epub 2020 Dec 3.PMID: 33275094 Review.
- Tocilizumab: From Rheumatic Diseases to COVID-19.Raiteri A, Piscaglia F, Granito A, Tovoli F.Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.PMID: 33719967 Review.